Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives
Clinical Breast Cancer · 2025
DOI: 10.1016/j.clbc.2025.04.011 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Clinical Breast Cancer, 2025. Verfasst von Lars Asphaug und 27 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trials Unit, Oslo University Hospital, Oslo, Norway; Department of Health Management and Health Economics, Institute of Health and Society, …. Hauptthemen laut MEDLINE: Breast Neoplasms, Gene Expression Profiling. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Norwegian Cancer Society, Pink Ribbon Foundation, Nasjonalt program for klinisk behandlingsforskning i spesialisthelsetjenesten.
Abstract (Originalsprache)
BACKGROUND: Gene expression profiling tests such as the Prosigna-assay are used to aid adjuvant treatment decisions in hormone receptor positive (HR+) HER2 negative (HER2-) early breast cancer (EBC). In this evaluation, the cost-effectiveness of Prosigna against immunohistochemical (IHC) markers including Ki-67, was evaluated from the Norwegian healthcare- and societal perspective. MATERIALS AND METHODS: The treatment decision impact of Prosigna was tested in the prospective, observational EMIT-1 trial. Using individual data collected the first 12 months post-surgery, a decision model was built to project the economic consequences of using the Prosigna compared to IHC-markers for the adjuvant treatment decisions. Health benefits were measured by cost per quality-adjusted life-years (QALYs) and data on income and welfare benefit was obtained from Statistics Norway. RESULTS: Of 2,178 HR+/HER2- pN0 EBC patients in the EMIT-1 trial, 1,985 had available health economic data and 1,850 had complete income and welfare benefit records. Including all pN0 patients in the Prosigna-test strategy, the test was above the cost-effective threshold (€26,000; incremental cost-per QALY gained (ICER) €255,622) in a healthcare sector perspective. Incorporating also productivity costs, Prosigna was cost-saving (ICER €-435,677). Restricting Prosigna-testing to patients assessed as clear/uncertain chemotherapy candidates, the strategy was cost-effective in both the healthcare and societal perspective (ICER €8884 and €-620170, respectively). CONCLUSIONS: Using the Prosigna-assay for all HR+/HER2- pN0 EBC patients was not cost-effective from a healthcare perspective, but from the societal perspective it was cost-saving. Selecting patients who are clear/uncertain candidates for chemotherapy based on IHC-classification, Prosigna is cost-effective from both perspectives.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trials Unit, Oslo University Hospital, Oslo, Norway; Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway. Electronic address: larasp@ous-hf.no.
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway; Department of Pathology Haukeland University Hospital, Bergen, Norway.
- Department of Oncology, University of North Norway, Tromsø, Norway; Department of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
- Department of Oncology, Hospital of Southern Norway, Kristiansand, Norway.
- Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital, Oslo, Norway.
- Department of Pathology, St Olavs Hospital, Trondheim, Norway.
Förderung
- The Norwegian Cancer Society
- Pink Ribbon Foundation
- Nasjonalt program for klinisk behandlingsforskning i spesialisthelsetjenesten
- Research Council of Norway
Zitieren
APA
Asphaug, L., Akslen, L. A., Blix, E. S., Boge, B., Borgen, E. F., Brekke, M. B., Falk, R. S., Geitvik, G. A., Gilje, B., Gravdehaug, B., Heie, A., Janssen, E., Kiserud, C. E., Kursetgjerde, T., Langerød, A., Lømo, J., Mannsåker, B., Mortensen, E., Olsson, P., …, & Naume, B. (2025). Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2025.04.011
Vancouver
Asphaug L, Akslen LA, Blix ES, Boge B, Borgen EF, Brekke MB, et al. Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives. Clinical Breast Cancer. 2025. doi:10.1016/j.clbc.2025.04.011
BibTeX
@article{Asphaug2025,
author = {Asphaug, Lars and Akslen, Lars A and Blix, Egil S and Boge, Beate and Borgen, Elin F and Brekke, Marianne B and Falk, Ragnhild S and Geitvik, Gry A and Gilje, Bjørnar and Gravdehaug, Berit and Heie, Anette and Janssen, Emiel and Kiserud, Cecilie E and Kursetgjerde, Torgunn and Langerød, Anita and Lømo, Jon and Mannsåker, Bård and Mortensen, Elin and Olsson, Pernilla and Porojnicu, Alina C and Raj, Sunil X and Roe, Oluf D and Russnes, Hege E G and Skjerven, Helle K and Songe-Møller, Silje and Vestlid, Magdalena A and Ohnstad, Hege O and Naume, Bjørn},
title = {Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives},
journal = {Clinical Breast Cancer},
year = {2025},
doi = {10.1016/j.clbc.2025.04.011}
}
EUVIMED